These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19058199)

  • 1. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
    Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
    Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
    Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
    Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
    Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
    Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
    Moawad EY
    J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
    Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
    Dziba JM; Ain KB
    J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.